AU2002221239A1 - Therapeutic benzimidazole compounds - Google Patents

Therapeutic benzimidazole compounds

Info

Publication number
AU2002221239A1
AU2002221239A1 AU2002221239A AU2123902A AU2002221239A1 AU 2002221239 A1 AU2002221239 A1 AU 2002221239A1 AU 2002221239 A AU2002221239 A AU 2002221239A AU 2123902 A AU2123902 A AU 2123902A AU 2002221239 A1 AU2002221239 A1 AU 2002221239A1
Authority
AU
Australia
Prior art keywords
therapeutic
benzimidazole compounds
benzimidazole
compounds
therapeutic benzimidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002221239A
Inventor
Bernard Barlaam
Steven Dock
James Folmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0100008A external-priority patent/SE0100008D0/en
Priority claimed from SE0100009A external-priority patent/SE0100009D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2002221239A1 publication Critical patent/AU2002221239A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
AU2002221239A 2000-12-07 2001-12-07 Therapeutic benzimidazole compounds Abandoned AU2002221239A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US25177600P 2000-12-07 2000-12-07
US25177300P 2000-12-07 2000-12-07
US60251773 2000-12-07
US60251776 2000-12-07
SE0100009 2001-01-02
SE0100008 2001-01-02
SE0100008A SE0100008D0 (en) 2001-01-02 2001-01-02 Therapeutic compounds
SE0100009A SE0100009D0 (en) 2001-01-02 2001-01-02 Therapeutic compounds
PCT/SE2001/002725 WO2002046168A1 (en) 2000-12-07 2001-12-07 Therapeutic benzimidazole compounds

Publications (1)

Publication Number Publication Date
AU2002221239A1 true AU2002221239A1 (en) 2002-06-18

Family

ID=27484529

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002221239A Abandoned AU2002221239A1 (en) 2000-12-07 2001-12-07 Therapeutic benzimidazole compounds

Country Status (5)

Country Link
US (1) US20070004713A1 (en)
EP (1) EP1341768A1 (en)
JP (1) JP2004515496A (en)
AU (1) AU2002221239A1 (en)
WO (1) WO2002046168A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
UA83620C2 (en) * 2001-12-05 2008-08-11 Уайт Substituted benzoxazoles and analogues as estrogenic agents
ES2335276T3 (en) * 2002-03-13 2010-03-24 Array Biopharma, Inc. DERIVATIVES OF BENCIMIDAZOL RENTED N3 AS INHIBITORS OF MEK.
US20040002524A1 (en) * 2002-06-24 2004-01-01 Richard Chesworth Benzimidazole compounds and their use as estrogen agonists/antagonists
MXPA05002040A (en) 2002-08-19 2005-12-12 Lorus Therapeutics Inc 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents.
DK1587821T3 (en) 2002-12-19 2008-11-10 Scripps Research Inst Compositions and Methods for Stabilizing Transthyretin and Inhibiting Transthyretin Failure
TW200500065A (en) * 2003-05-21 2005-01-01 Wyeth Corp Antiarthritic combinations
SE0302573D0 (en) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
US8969372B2 (en) 2003-11-14 2015-03-03 Aptose Boisciences Inc. Aryl imidazoles and their use as anti-cancer agents
JP2007538103A (en) 2004-05-20 2007-12-27 ザ スクリップス リサーチ インスティテュート Transthyretin stabilization
AU2005280178A1 (en) * 2004-08-26 2006-03-09 Wyeth Prodrug substituted benzoxazoles as estrogenic agents
BRPI0514974A (en) 2004-09-07 2008-07-01 Wyeth Corp compound, composition, methods of treating or inhibiting a disease or condition, free radical-induced disease states in a mammal, damage to the joint secondary to arthroscopic or surgical procedures in a mammal, infertility in a mammal, lowering cholesterol levels, triglycerides, lp (a), or ldl, to provide cognition or neuroprotection enhancement, contraception in a mammal, and to prepare a compound, and, product
ATE545644T1 (en) 2004-09-24 2012-03-15 Astrazeneca Ab BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, PRODUCTION THEREOF AND USES THEREOF I
KR20070072598A (en) * 2004-10-19 2007-07-04 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 Indole and benzimidazole derivatives
MX2007005290A (en) 2004-11-02 2007-07-09 Pfizer Sulfonyl benzimidazole derivatives.
AU2005316561A1 (en) * 2004-12-17 2006-06-22 Wyeth The uses of estrogen beta agonists to treat cognitive diseases
DE102005012873B4 (en) * 2005-03-19 2007-05-03 Sanofi-Aventis Deutschland Gmbh Aminocarbonyl-substituted 8-N-benzimidazoles, process for their preparation and their use as pharmaceuticals
CA2611032C (en) 2005-05-25 2012-01-17 Genesense Technologies Inc. 2-indolyl imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
JP2009530274A (en) * 2006-03-15 2009-08-27 ワイス N-substituted azacyclylamine compounds as histamine-3 antagonists
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
PE20081152A1 (en) * 2006-10-06 2008-08-10 Wyeth Corp N-SUBSTITUTED AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS
AR063311A1 (en) 2006-10-18 2009-01-21 Novartis Ag ORGANIC COMPOUNDS
MX2009006706A (en) 2006-12-22 2009-07-02 Astex Therapeutics Ltd Bicyclic heterocyclic compounds as fgfr inhibitors.
JP5442449B2 (en) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド New compounds
EP2106399A2 (en) 2007-01-05 2009-10-07 Novartis AG Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
EA019833B1 (en) 2007-01-22 2014-06-30 ДЖиТиЭкс, ИНК. Nuclear receptor binding agents
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
CN101990433B (en) 2008-02-07 2014-11-05 马萨诸塞眼科耳科诊所 Compounds that enhance atoh-1 expression
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US8501957B2 (en) * 2008-12-10 2013-08-06 China Medical University Benzimidazole compounds and their use as anticancer agents
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
EP2493310A4 (en) * 2009-10-27 2014-03-12 Glaxosmithkline Llc Benzimidazoles as fatty acid synthase inhibitors
AU2010314891A1 (en) 2009-11-06 2012-06-07 Vanderbilt University Aryl and heteroaryl sulfones as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
TWI458714B (en) * 2009-12-10 2014-11-01 Univ China Medical Benzimidazole compounds and their use
JP5782234B2 (en) * 2010-06-16 2015-09-24 チャイナ メディカル ユニヴァーシティーＣｈｉｎａ Ｍｅｄｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ Benzimidazole compounds and uses thereof
EP2397471A1 (en) * 2010-06-16 2011-12-21 China Medical University Benzimidazole compounds and their use
US20130196971A1 (en) * 2010-09-17 2013-08-01 Christopher Joseph Aquino Fatty acid synthase inhibitors
CA2847293C (en) 2011-09-16 2017-03-28 Richard Frederic Labaudiniere Solid forms of a transthyretin dissociation inhibitor
EP2757882B1 (en) 2011-09-22 2020-11-04 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
US9351973B2 (en) 2011-09-22 2016-05-31 Merck Sharp & Dohme Corp. Pyrazolopyridyl compounds as aldosterone synthase inhibitors
EP2757883B1 (en) 2011-09-22 2021-01-13 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
WO2014055595A1 (en) 2012-10-05 2014-04-10 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitiors related applications
AU2014235962A1 (en) 2013-03-20 2015-09-10 Aptose Biosciences Inc. 2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
JP6946000B2 (en) 2013-10-04 2021-10-06 アプトース バイオサイエンシーズ， インコーポレイテッド Compositions and Methods for the Treatment of Cancer
CN104072425B (en) * 2014-07-09 2016-12-07 大连理工大学 Benzimidazoles compound and application thereof
WO2019089511A1 (en) 2017-10-30 2019-05-09 Aptose Biosciences Inc. Aryl imidazoles for the treatment of cancer
CN108456171B (en) * 2018-03-16 2021-07-27 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） FLT3/ITD mutant inhibitor and application thereof in tumor prevention and treatment medicines
JP2022508648A (en) 2018-10-05 2022-01-19 アンナプルナ バイオ インコーポレイテッド Compounds and compositions for treating conditions associated with APJ receptor activity
WO2021112538A1 (en) * 2019-12-02 2021-06-10 Hyundai Pharm Co., Ltd. Glp-1 receptor agonist
WO2023165523A1 (en) * 2022-03-01 2023-09-07 上海璎黎药业有限公司 Aromatic ring-substituted methoxy derivative and use thereof
WO2024029819A1 (en) * 2022-08-01 2024-02-08 경희대학교 산학협력단 Pharmaceutical composition containing benzimidazole derivative or pharmaceutically acceptable salt thereof, and method for preparing same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3152142A (en) * 1962-05-24 1964-10-06 Dow Chemical Co Benzimidazole compounds
US3632397A (en) * 1966-01-26 1972-01-04 Lilly Co Eli Method of controlling weeds pre-emergently
US4093726A (en) * 1976-12-02 1978-06-06 Abbott Laboratories N-(2-benzimidazolyl)-piperazines
GB2053215B (en) * 1979-06-25 1983-04-07 May & Baker Ltd Benzimidazole derivatives
JP2869561B2 (en) * 1989-05-22 1999-03-10 大塚製薬株式会社 Platelet adhesion inhibitor
FR2677020B1 (en) * 1991-05-31 1993-08-27 Cird Galderma COMPOUNDS DERIVED FROM BENZIMIDAZOLE, THEIR PREPARATION PROCESS AND THEIR USE IN THE THERAPEUTIC AND COSMETIC FIELDS.
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
IL113472A0 (en) * 1994-04-29 1995-07-31 Lilly Co Eli Non-peptidyl tachykinin receptor antogonists
WO1997012613A1 (en) * 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
DE69635135T2 (en) * 1995-12-28 2006-07-06 Fujisawa Pharmaceutical Co., Ltd. benzimidazole derivatives
EP0871442A1 (en) * 1996-01-09 1998-10-21 Eli Lilly And Company Benzimidzolyl neuropeptide y receptor antagonists
JP2000026430A (en) * 1998-07-02 2000-01-25 Taisho Pharmaceut Co Ltd 2,5,6-substituted benzimidazole compound derivative
GB9814620D0 (en) * 1998-07-06 1998-09-02 Karobio Ab Vasculoprotector
JP2000095767A (en) * 1998-09-28 2000-04-04 Takeda Chem Ind Ltd Antagonist for gonadotrophic hormone-releasing hormone
EP1173164A2 (en) * 1999-04-16 2002-01-23 AstraZeneca AB Estrogen receptor-beta ligands
GB9914825D0 (en) * 1999-06-24 1999-08-25 Smithkline Beecham Spa Novel compounds
JP2001192372A (en) * 2000-01-11 2001-07-17 Teijin Ltd Benzimidazole derivative

Also Published As

Publication number Publication date
JP2004515496A (en) 2004-05-27
WO2002046168A1 (en) 2002-06-13
US20070004713A1 (en) 2007-01-04
EP1341768A1 (en) 2003-09-10

Similar Documents

Publication Publication Date Title
AU2002221239A1 (en) Therapeutic benzimidazole compounds
AU2002222853A1 (en) Therapeutic compounds
AU2001252135A1 (en) Therapeutic agents
AU2001230426A1 (en) Therapeutic morpholino-substituted compounds
GB0023983D0 (en) Therapeutic compounds
GB0008710D0 (en) Therapeutic compounds
GB0016681D0 (en) Therapeutic compounds
AU2002224038A1 (en) Benzimidazole derivatives
GB0028583D0 (en) Therapeutic compounds
AU2002353739A1 (en) Therapeutic compounds
AU2451500A (en) Therapeutic agents
GB9900222D0 (en) Therapeutic compounds
AU2001273903A1 (en) Therapeutic agents
AU2002332178A1 (en) Benzimidazole derivatives
AU2001275696A1 (en) Therapeutic agent
AU2001292578A1 (en) Pharmaceutical compounds
AU2000238755A1 (en) Dermatological compounds
GB0013105D0 (en) Therapeutic compounds
AU2002309243A1 (en) Heterocyclic compounds for therapeutic use
AU5817400A (en) Therapeutic agents
AU2002216577A1 (en) Therapeutic compounds
AUPR223700A0 (en) Therapeutic methods - ii
AU5817500A (en) Therapeutic agents
AUPP836999A0 (en) Therapeutic compounds
AUPR817901A0 (en) Therapeutic compounds